Regeneron dips on initial Dupixent sales

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares declined $17.09 to $491.62 on Monday after partner Sanofi (Euronext:SAN; NYSE:SNY) reported 2Q17 sales of atopic dermatitis drug Dupixent dupilumab that were lighter than investors anticipated.

Sell-side consensus estimates called for $33 million in sales, the drug’s first full quarter on the market, and many investors were expecting a beat based on the strength of early prescription volume trends. The pharma reported sales of €26 million ($30.5 million)...